HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Mechanisms underlying early development of pulmonary vascular obstructive disease in Down syndrome: An imbalance in biosynthesis of thromboxane A2 and prostacyclin.

Abstract
Patients with Down syndrome (DS) and a left-to-right shunt often develop early severe pulmonary hypertension (PH) and pulmonary vascular obstructive disease (PVOD); the pathophysiological mechanisms underlying the development of these complications are yet to be determined. To investigate the mechanisms, we evaluated the biosynthesis of thromboxane (TX) A(2) and prostacyclin (PGI(2)) in four groups of infants, cross-classified as shown below, by measuring the urinary excretion levels of 11-dehydro-TXB(2) and 2,3-dinor-6-keto-PGF(1alpha): DS infants with a left-to-right shunt and PH (D-PH, n = 18), DS infants without congenital heart defect (D-C, n = 8), non-DS infants with a left-to-right shunt and PH (ND-PH, n = 12), and non-DS infants without congenital heart defect (ND-C, n = 22). The urinary excretion ratios of 11-dehydro-TXB(2) to 2,3-dinor-6-keto-PGF(1alpha) in the D-PH, D-C, ND-PH, and ND-C groups were 7.69, 4.71, 2.10, and 2.27, respectively. The ratio of 11-dehydro-TXB(2) to 2,3-dinor-6-keto-PGF(1alpha) was higher in the presence of DS (P < 0.001), independently of the presence of PH (P = 0.297). The predominant biosynthesis of TXA(2) over PGI(2), leading to vasoconstriction, was observed in DS infants, irrespective of the presence/absence of PH. This imbalance in the biosynthesis of vasoactive eicosanoids may account for the rapid progression of PVOD in DS infants with a left-to-right shunt.
AuthorsHiroyuki Fukushima, Kenjiro Kosaki, Reiko Sato, Tatsuhiko Yagihashi, Ryohei Gatayama, Kazuki Kodo, Takuya Hayashi, Maki Nakazawa, Takatoshi Tsuchihashi, Jun Maeda, Yoshifumi Kojima, Hiroyuki Yamagishi, Takao Takahashi
JournalAmerican journal of medical genetics. Part A (Am J Med Genet A) Vol. 152A Issue 8 Pg. 1919-24 (Aug 2010) ISSN: 1552-4833 [Electronic] United States
PMID20583254 (Publication Type: Journal Article)
Chemical References
  • Thromboxane B2
  • Thromboxane A2
  • 6-Ketoprostaglandin F1 alpha
  • 2,3-dinor-6-ketoprostaglandin F1alpha
  • 11-dehydro-thromboxane B2
  • Epoprostenol
Topics
  • 6-Ketoprostaglandin F1 alpha (analogs & derivatives, urine)
  • Child, Preschool
  • Cross-Sectional Studies
  • Down Syndrome (complications, metabolism)
  • Epoprostenol (biosynthesis)
  • Female
  • Heart Defects, Congenital (etiology, metabolism)
  • Humans
  • Hypertension, Pulmonary (etiology, metabolism)
  • Infant
  • Lung Diseases, Obstructive (etiology, metabolism)
  • Male
  • Prognosis
  • Pulmonary Heart Disease (etiology, metabolism)
  • Radioimmunoassay
  • Thromboxane A2 (biosynthesis)
  • Thromboxane B2 (analogs & derivatives, urine)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: